We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CPAY:NYSECorpay, Inc. Analysis

Data as of 2026-05-23 - not real-time

$347.90

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Corpay delivered a "blowout" Q1 FY2026, posting 25.4% year‑over‑year revenue growth to $1.26 billion and a non‑GAAP EPS of $5.80 that topped consensus by 6%, prompting the company to raise its full‑year revenue guidance to $5.29 billion. The stock is trading at $347.9, comfortably above its 20‑day SMA of $326 and the 50‑day SMA of $314, while still below the 200‑day SMA of $309, signaling a bullish momentum that is reinforced by a MACD histogram of +2.38 and an RSI of 63, well under the overbought threshold. Volume has remained stable, and the price is perched near the calculated resistance of $354.97 with a solid support floor at $298.46, suggesting limited upside in the immediate term but room to test the resistance on further earnings momentum.
From a valuation perspective, the discounted cash‑flow model implies a fair value near $1,019, indicating the market is pricing the stock at a roughly 12% discount to intrinsic value. Strong operating margins (41% operating, 25% net) and a free cash flow conversion of over $2 billion underscore the company’s cash‑generating efficiency, yet a debt‑to‑equity ratio above 270% and a price‑to‑book of 6.55 flag balance‑sheet leverage concerns. The absence of a dividend makes the stock a pure growth play, and while beta around 1.2 and a 30‑day volatility of 47% point to heightened price swings, the sector’s technology‑infrastructure backdrop and the company’s U.S.‑centric operations temper broader regulatory and geographic risks.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Bullish MACD and SMA alignment
  • Price near short‑term resistance
  • Stable trading volume

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust 25% revenue growth and raised guidance
  • Undervalued relative to DCF fair value
  • High operating and net margins

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Recurring payments franchise with strong cash generation
  • Strategic positioning in corporate spend management
  • Long‑term upside potential despite current leverage

Key Metrics & Analysis

Financial Health

Revenue Growth25.40%
Profit Margin24.60%
P/E Ratio20.8
ROE32.12%
ROA6.19%
Debt/Equity271.34
P/B Ratio6.6
Op. Cash Flow$1.5B
Free Cash Flow$2.1B
Industry P/E39.5

Technical Analysis

TrendBullish
RSI63.1
Support$298.46
Resistance$354.97
MA 20$326.04
MA 50$313.68
MA 200$308.99
MACDBullish
VolumeStable
Fear & Greed Index91.61

Valuation

Fair Value$1,018.81
Target Price$389.79
Upside/Downside12.04%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta1.24
Volatility46.87%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.